Tempest Therapeutics Inc.

06/11/2025 | Press release | Distributed by Public on 06/11/2025 05:41

Material Event (Form 8-K)

Item 8.01

Other Information.

On June 11, 2025, Tempest Therapeutics, Inc. (the "Company") delivered written notice to Jefferies LLC ("Jefferies") that it was suspending and terminating the prospectus supplement, dated February 6, 2025, related to the Company's common stock, $0.001 par value per share (the "ATM Prospectus"), issuable pursuant to the terms of the Open Market Sale AgreementSM, dated June 20, 2024 (the "Sales Agreement"), by and between the Company and Jefferies. The Company will not make any sales of its securities pursuant to the Sales Agreement, unless and until a new prospectus, prospectus supplement or a new registration statement is filed. Other than the termination of the ATM Prospectus, the Sales Agreement remains in full force and effect. A copy of the Sales Agreement was filed as Exhibit 1.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on June 20, 2024.

Tempest Therapeutics Inc. published this content on June 11, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 11, 2025 at 11:41 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io